Literature DB >> 33708401

Crystallographic models of SARS-CoV-2 3CLpro: in-depth assessment of structure quality and validation.

Mariusz Jaskolski1,2, Zbigniew Dauter3, Ivan G Shabalin4, Miroslaw Gilski1,2, Dariusz Brzezinski2,5, Marcin Kowiel2, Bernhard Rupp6,7, Alexander Wlodawer3.   

Abstract

The appearance at the end of 2019 of the new n class="Species">SARS-CoV-2 coronavirus led to an unprecedented response by the structural biology community, resulting in the rapid determination of many hundreds of structures of proteins encoded by the virus. As part of an effort to analyze and, if necessary, remediate these structures as deposited in the Protein Data Bank (PDB), this work presents a detailed analysis of 81 crystal structures of the main protease 3CLpro, an important target for the design of drugs against COVID-19. The structures of the unliganded enzyme and its complexes with a number of inhibitors were determined by multiple research groups using different experimental approaches and conditions; the resulting structures span 13 different polymorphs representing seven space groups. The structures of the enzyme itself, all determined by molecular replacement, are highly similar, with the exception of one polymorph with a different inter-domain orientation. However, a number of complexes with bound inhibitors were found to pose significant problems. Some of these could be traced to faulty definitions of geometrical restraints for ligands and to the general problem of a lack of such information in the PDB depositions. Several problems with ligand definition in the PDB itself were also noted. In several cases extensive corrections to the models were necessary to adhere to the evidence of the electron-density maps. Taken together, this analysis of a large number of structures of a single, medically important protein, all determined within less than a year using modern experimental tools, should be useful in future studies of other systems of high interest to the biomedical community. © Mariusz Jaskolski et al. 2021.

Entities:  

Keywords:  COVID-19; Protein Data Bank; SARS-CoV-2; coronavirus; ligand validation; reproducibility; structure-guided drug discovery; viral proteases

Year:  2021        PMID: 33708401      PMCID: PMC7924243          DOI: 10.1107/S2052252521001159

Source DB:  PubMed          Journal:  IUCrJ        ISSN: 2052-2525            Impact factor:   4.769


  7 in total

1.  Combining X-rays, neutrons and electrons, and NMR, for precision and accuracy in structure-function studies.

Authors:  John R Helliwell
Journal:  Acta Crystallogr A Found Adv       Date:  2021-05-04       Impact factor: 2.290

2.  Some lessons from COVID: science and communication.

Authors:  Edward N Baker
Journal:  IUCrJ       Date:  2021-04-15       Impact factor: 4.769

3.  Production of a functionally active recombinant SARS-CoV-2 (COVID-19) 3C-like protease and a soluble inactive 3C-like protease-RBD chimeric in a prokaryotic expression system.

Authors:  Carolina De Marco Verissimo; Jesús López Corrales; Amber L Dorey; Krystyna Cwiklinski; Richard Lalor; Nichola Eliza Davies Calvani; Heather L Jewhurst; Andrew Flaus; Sean Doyle; John P Dalton
Journal:  Epidemiol Infect       Date:  2022-06-20       Impact factor: 4.434

4.  The tem-per-ature-dependent conformational ensemble of SARS-CoV-2 main protease (Mpro).

Authors:  Ali Ebrahim; Blake T Riley; Desigan Kumaran; Babak Andi; Martin R Fuchs; Sean McSweeney; Daniel A Keedy
Journal:  IUCrJ       Date:  2022-08-17       Impact factor: 5.588

5.  Structural and functional characterization of NEMO cleavage by SARS-CoV-2 3CLpro.

Authors:  Mikhail A Hameedi; Erica T Prates; Michael R Garvin; Irimpan I Mathews; B Kirtley Amos; Omar Demerdash; Mark Bechthold; Mamta Iyer; Simin Rahighi; Daniel W Kneller; Andrey Kovalevsky; Stephan Irle; Van-Quan Vuong; Julie C Mitchell; Audrey Labbe; Stephanie Galanie; Soichi Wakatsuki; Daniel Jacobson
Journal:  Nat Commun       Date:  2022-09-08       Impact factor: 17.694

6.  The four Rs and crystal structure analysis: reliability, reproducibility, replicability and reusability.

Authors:  John R Helliwell; Chiara Massera
Journal:  J Appl Crystallogr       Date:  2022-08-24       Impact factor: 4.868

7.  Prioritisation of Compounds for 3CLpro Inhibitor Development on SARS-CoV-2 Variants.

Authors:  Marko Jukič; Blaž Škrlj; Gašper Tomšič; Sebastian Pleško; Črtomir Podlipnik; Urban Bren
Journal:  Molecules       Date:  2021-05-18       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.